Hib-DTaP vaccine - GSK
Alternative Names: Hib-DTP-acellular vaccine - GSK; Infanrix-HibLatest Information Update: 02 Aug 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Pertussis; Tetanus
Most Recent Events
- 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 06 Apr 2000 Launched for Diphtheria in United Kingdom (IM)
- 06 Apr 2000 Launched for Haemophilus infections in United Kingdom (IM)